14305 results for ""Pennsylvania+German"+ACS+study+'Socius'+open+access"

in 18.55 milliseconds.

• Hematology Research Unit Helsinki Data Access Committee

  Dac EGAC00001003456

• Hematology Research Unit Helsinki Data Access Committee

  Dac EGAC00001003457

• 2021-inform-RIG-WES data access

  Dac EGAC00001002186

• Epi2Diag methylation datasets Data Access Committee

  Dac EGAC00001003531

• CRUK Pancreatic neuroendocrine tumours Data Access Committee

  Dac EGAC00001002938

• Mesothelial peritoneal adhesions profile Data Access Commitee

  Dac EGAC00001002389

• Data Access Committee for data from EGAS00001004454

  Dac EGAC00001002077

• Data Access Committee for data from EGAS00001006662

  Dac EGAC00001003009

• Data Access Committee for data from EGAS00001005944

  Dac EGAC00001002583

• Transcriptomic profiles studies CAREs group - IDIBGI

  The purpose of this DAC document is to outline the principles and procedures governing access to the transcriptomic data generated from endothelial progenitor cells, or any biological origin from patients. Data Access Policy: 1) Access to this dataset is restricted and subject to approval by the DAC to ensure ethical and legal compliance. 2) The DAC reserves the right to evaluate all applications for access based on: 2.1) The scientific validity and merit of the proposed research. 2.2) The ethical considerations and adherence to data protection regulations, including GDPR. 2.3) The qualifications and affiliations of the applicants. 3) Applicants must submit a detailed research proposal, including objectives, methods, and anticipated outcomes. 4) Data usage is limited to the specified research project approved by the DAC. Any secondary use of the data requires additional approval. Confidentiality: All applicants must agree to maintain the confidentiality of the dataset. Personal identifiers have been pseudonymized to protect patient privacy. Application Process: 1) Researchers must complete the application form provided by the DAC. 2) Submit proof of ethical approval and relevant certifications for their research project. 3) Provide a signed agreement affirming adherence to the DAC's terms and conditions.

  Dac EGAC50000000607

• RNA sequencing of periprostatic fat after a 6 month deep androgen deprivation therapy

  Androgen deprivation therapy treated patients (n=11) were recruited from an open label neoadjuvant phase II study in which patients with high-risk disease received a ‘supercastration’ regimen consisting of degarelix 240/80 mg subcutaneously every four weeks; abiraterone acetate 500 mg orally daily titrating upwards every two weeks by 250 mg to a final dose of 1000 mg daily; bicalutamide 50 mg orally daily; and prednisolone 5 mg orally twice daily for a total of 6 months (Australian New Zealand Clinical Trials Registry 12612000772842). Untreated patients with similar pre-treatment characteristics were obtained from a prospective prostatectomy biorepository22,23. Prior to ligation of the dorsal venous complex and prostate pedicles, the anterior prostate was defatted and the specimen was removed immediately, placed in a sterile container and transferred on ice for long-term storage in the vapour phase of liquid nitrogen. A total of 50–100 µg of adipose tissue was separated from fresh frozen samples stored at −160°C. RNA was isolated using the Qiagen RNeasy Lipid Tissue Mini Kit and eluted in 35 µL nuclease-free water. 0.5–1 µg of total RNA was used as the input for cDNA library synthesis using TruSeq RNA Sample Prep Kit v2 (Illumina), and libraries were constructed according to manufacturer’s instructions. Samples were sequenced on a HiSeq 2500 (Illumina) using 101 base paired-end chemistry, aiming for 50 million mapped paired-end reads per sample.

  Dataset EGAD00001004971

• ICGC Data Access Compliance Office

  Dac EGAC00001003040

• Tampere University Hospital Leukemia Research Data Access Committee

  Dac EGAC00001003278

• Nencki Institute NGS Core Facility Data Access Commitee

  Dac EGAC00001001676

• MD Anderson Lymphoma & Myeloma Data Access Committee

  Dac EGAC00001002990

• Lung Cancer Single-cell Data Access Committee

  Dac EGAC00001001220

• Tampere University Hospital Leukemia Research Data Access Committee

  Dac EGAC00001003137

• Data Access Commitee for skin scRNA-seq

  Dac EGAC00001003129

• Department of Gastroenterology and Hepatology Data Access Committee

  Dac EGAC00001003361

• DATA ACCESS COMMITTEE BCTL-IRIBHM

  Dac EGAC00001000120

• Breast Cancer Cell Line Data Access Committee

  Dac EGAC00001000134

• The Sample and Data Access Committee (SDAC) of CARTaGENE

  Dac EGAC00001000525

• Maastricht Irritable Bowel Syndrome Metagenomics Data Access Commitee

  Dac EGAC00001000535

• Simons Genome Diversity Project Data Access Committee

  Dac EGAC00001000541

• The Ovarian Cancer Association Consortium Data Access Committee

  Dac EGAC00001000616

• Data Access Committee for Institut Curie Data

  Dac EGAC00001000623

• Botswana 15 autosomal unlinked microsatellites Data Access Consortium

  Dac EGAC00001000636

• Data Access Committee for Institut Curie

  Dac EGAC00001000670

• Tel Aviv University Human BiPSC Data Access Committee

  Dac EGAC00001000735

• Whole genome sequencing of Hepatoblastoma Data Access Committee

  Dac EGAC00001000798

• Gastrointestinal Organoid Genomic Profiling ICR Data Access Committee

  Dac EGAC00001000807

• Spatial Maps of Prostate Cancer Transcriptomes Data Access

  Dac EGAC00001000913

• High hyperdiploid ALL sequencing data Data Access Commitee

  Dac EGAC00001000950

• Data Access Commitee for gastric cancer ascites

  Dac EGAC00001001026

• N.N. Petrov Institute of Oncology Data Access Committee

  Dac EGAC00001001361

• IIS - Fundacion Jimenez Diaz Data Access Committee

  Dac EGAC00001001392

• SGI Single-cell team GC Data Access Committee

  Dac EGAC00001001420

• Human Development Single Cell Sequencing Data Access Commitee

  Dac EGAC00001001431

• Peter MacCallum Cancer Centre Research Data Access Committee

  Dac EGAC00001001500

• MM Liquid Biopsy Data Access Commitee (array set)

  Dac EGAC00001001530

• Long-read trio sequencing Team Data Access Commitee

  Dac EGAC00001001532

• Hereditary Cancer Diagnostics with I2HCP Data Access Comitee

  Dac EGAC00001001541

• Human Development Single Cell Sequencing Data Access Commitee

  Dac EGAC00001001557

• Inherited Predisposition to Cancer Projects Data Access Committee

  Dac EGAC00001001565

• Immunogenomics of Colorectal Cancer Data Access Committee

  Dac EGAC00001001596

• UZ Ghent Prostate Cancer Team Data Access Committee

  Dac EGAC00001001608

• Beijing Institute of Radiation Medicine Data Access Commitee

  Dac EGAC00001001616

• Primary tumor and metastatic breast cancer data access

  Dac EGAC00001001687

• Cancer Alliance Data Access Committee

  Dac EGAC00001001641

• DKFZ Neuroblastoma Genomics (B087) - Data Access Committee

  Dac EGAC00001001669

• DKFZ Neuroblastoma Genomics (B087) - Data Access Committee

  Dac EGAC00001001670

• Board considering access to BELOB RNA-seq data

  Dac EGAC00001001686

• Peter MacCallum Cancer Centre Research Data Access Committee

  Dac EGAC00001001906

• VIB CCB Translational Genetics Data Access Commitee

  Dac EGAC00001001928

• Replication Repair Deficiency Data Access Committee

  Dac EGAC00001001936

• Singapore Gastric Cancer Consortium Data Access Committee

  Dac EGAC00001001955

• VIB CCB Translational Genetics Data Access Committee

  Dac EGAC00001001975

• Peter MacCallum Cancer Centre Research Data Access Committee

  Dac EGAC00001001988

• CIN Methylation Data Access Committee

  Dac EGAC00001001990

• Epigenomic heterogeneity of lung adenocarcinoma Data Access Committee

  Dac EGAC00001002025

• BGI-Single Cell Clinical application Data Access Commitee

  Dac EGAC00001002092

• NHL CD19 CAR-T Treatment Data Access Committee

  Dac EGAC00001002152

• Data Access Committee for data from EGAS00001005196

  Dac EGAC00001002215

• Single-cell Omics Glioma Team Data Access Committee

  Dac EGAC00001002256

• PGDx elio tissue complete Validation Data Access Committee

  Dac EGAC00001002278

• Data Access Commitee for COVID-19 longitudinal data

  Dac EGAC00001002396

• Women’s Health Integrated Research Center Data Access Committee

  Dac EGAC00001002406

• Haematopoietic stem cells and malignancies Data Access Comittee

  Dac EGAC00001002410

• Tampere University Hospital Leukemia Reserach Data Access Committee

  Dac EGAC00001002445

• Tampere University Hospital Leukemia Research Data Access Committee

  Dac EGAC00001002489

• Berlin Neuroblastoma Patient Genomics Data Access Committee DAC

  Dac EGAC00001002532

• MPM CDK4/6 inhibition Data Access Committee

  Dac EGAC00001002620

• Cell Free Plasma Methyl-DNA Data Access Committee

  Dac EGAC00001002626

• MSKCC Colorectal Cancer Plasma WGS Data Access Comittee

  Dac EGAC00001002741

• SAHMRI Acute Lymphoblastic Leukaemia Data Access Committee

  Dac EGAC00001002790

• Pfizer Clinical Trial Data Sharing Data Access Committee

  Dac EGAC00001002826

• Peter MacCallum Cancer Centre Research Data Access Committee

  Dac EGAC00001002829

• Data Access Committee for the Radovanovic group

  Dac EGAC00001002942

• NIBIT-M4 Data Access Commitee

  Dac EGAC00001002947

• VIB CCB Translational Genetics Data Access Commitee

  Dac EGAC00001002959

• Data Access Commitee for sputum bacterial microbiome data

  Dac EGAC00001003004

• Tampere University Hospital Leukemia Research Data Access Committee

  Dac EGAC00001003156

• NOWAC blood-breast cancer Data Access Committee

  Dac EGAC01000000024

• Molecular Pathology of Lymphoid Neoplasms Data Access Commitee

  Dac EGAC00001003346

• VIB CCB Translational Genetics Data Access Committee

  Dac EGAC00001003415

• IRIBHM computational biology data access committee

  Dac EGAC00001003436

• Data Access Committee for data from EGAS00001007708

  Dac EGAC00001003486

• Singapore Gastric Cancer Consortium Data Access Committee

  Dac EGAC00001002251

• DAC_ICARUS_BREAST01

  Data access committee for ICARUS BREAST 01

  Dac EGAC50000000344

• Genome Asia 100K Consortium

  Dac EGAC00001001439

• Department of Gastroenterology and Hepatology Data Access Committee

  Dac EGAC00001003021

• HaikaLab Immuno-Oncology research group Data Access Committee

  Dac EGAC50000000387

• Data Access Committee for data from EGAS00001007484

  Dac EGAC00001003459

• Walter and Eliza Hall Institute Research Data Access Committee

  Dac EGAC00001003583

• Study of Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in Idiopathic Pulmonary Fibrosis (CleanUP IPF-BioLINCC)

  Data Access NOTE: Please refer to the “Authorized Access” section below for information about how access to the data from this accession differs from many other dbGaP accessions. Objectives To investigate whether the addition of antimicrobial treatments improves outcomes compared to usual care alone among patients with idiopathic pulmonary fibrosis. Background Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease. Lung dysbiosis, characterized by increased bacterial load and/or loss of diversity, has been reported in patients with IPF and may contribute to hospitalization and death. Clinical trials investigating other chronic disorders suggest that antimicrobial therapy favorably alters the lung microbial community. The CleanUP IPF study was initiated to determine if an antimicrobial treatment reduces respiratory hospitalization or death among patients with IPF. Participants A total of 513 participants were enrolled. 254 participants were randomized to receive antimicrobials, of those 128 were randomized to receive co-trimoxazole and 126 were randomized to receive doxycycline. 259 participants were randomized to receive usual care alone. Design CleanUP IPF was a randomized, unblinded, multicenter study. Patients were randomized to receive antimicrobials in addition to usual care or usual care alone. Antimicrobials included co-trimoxazole (trimethoprim 160 mg/sulfamethoxazole 800 mg twice daily plus folic acid 5 mg daily) or doxycycline (100 mg once daily if body weight Data collected included diffusion capacity of lungs for carbon monoxide (DLCO), forced vital capacity (FVC), and occurrence of severe adverse events. Several questionnaires were administered to assess quality of life, including the impacts of shortness of breath, fatigue, and chronic cough on participants. The primary end point was time to first nonelective respiratory hospitalization or all-cause mortality. The study was terminated early due to futility. Conclusions Among adults with idiopathic pulmonary fibrosis, the addition of co-trimoxazole or doxycycline to usual care, compared with usual care alone, did not significantly improve time to nonelective respiratory hospitalization or death. Martinez FJ, Yow E, Flaherty KR, et al. Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial. JAMA. 2021;325(18):1841-1851. doi:10.1001/jama.2021.4956

  Study phs004314

• Public Access Defibrillation Community Trial (PAD)(PAD-BioLINCC)

  Data Access NOTE: Please refer to the “Authorized Access” section below for information about how access to the data from this accession differs from many other dbGaP accessions. Objectives The Public Access Defibrillation (PAD) Community Trial sought to evaluate broad implementation of Public Access Defibrillators (PAD) in urban community units. Survival to hospital discharge of participants with out-of-hospital cardiac arrest was the main outcome measure. Survival was compared in community units (e.g., apartment or office buildings, gated communities, sports venues, senior centers, shopping malls) served by non-medical responders trained in CPR and use of automated external defibrillators (AEDs), to units receiving the traditional optimum community standard of care (i.e., rescuers trained to recognize a cardiac emergency, call 911, and initiate CPR). Background Sudden out-of-hospital cardiac arrest (OOH-CA) remains a significant cause of death, in spite of recent declines in overall mortality from cardiovascular disease. Existing methods of emergency resuscitation are inadequate due to time delays inherent in transporting trained responders with defibrillation capabilities to the side of the OOH-CA victim. Existing Emergency Medical Services (EMS) systems typically combine paramedic Emergency Medical Technician (EMT) services with some level of community involvement, such as bystander cardiopulmonary resuscitation (CPR) training. Some communities include automated external defibrillators (AEDs) at isolated sites or in mobile police or fire vehicles. Such an approach typically varies in effectiveness, with an incremental improvement in effectiveness seen in communities that organize and integrate services with the existing EMS system. However, optimal improvement in survival from sudden OOH-CA may require a program that utilizes volunteer non-medical responders (who may not have a traditional duty to respond to an emergency) trained to use AEDs. Participants The PAD trial was a prospective, randomized community based trial. More than 19,000 volunteer responders from 993 community units in 24 North American regions participated. The two study arms had similar unit and volunteer characteristics. Participants with treated out-of-hospital cardiac arrest in the two groups were similar in age (mean: 69.8 years), proportion of men (67 perecnt), rate of cardiac arrest in a public location (70 percent), and rate of witnessed cardiac arrest (72 percent). Conclusions Community units with volunteers trained in CPR and AEDs had significantly more participants surviving to hospital discharge than units with volunteers trained to use CPR only. There were 30 survivors among 128 definite cardiac arrests in the CPR+AED units and 15 survivors among 107 definite cardiac arrests in the CPR only units (p = 0.03). Serious adverse effects were rarely reported. No volunteers received inadvertent shocks, and no participants were shocked unnecessarily. AED maintenance problems were infrequent. A few participating volunteers reported severe stress related to responding to emergency situations. Although residential complexes represented 16% of the units and 29% of the treatable cardiac arrests, only 5% of the survivors were from residential complexes. Such information should be helpful for individual facilities that are considering implementing PAD programs. (NEJM 2004; 351:637-46).

  Study phs003858

• Whole Exome Sequences of Human Embryonic Stem Cell Lines

  Human embryonic stem cells (hESCs) are a powerful tool for the study of human development and can form the basis of cellular disease models or therapies. However, the genetic make-up and stability of hESCs has not been systematically studied at a genome-wide level with single nucleotide resolution. We therefore sequenced the whole exomes of widely available hESCs. The data generated has provided new insights about the nature of acquired variation and the genomic integrity of the cell lines. We anticipate that this online resource will enable investigators to access raw sequencing data in order to interrogate cell lines for different disease and trait-associated genetic variants.

  Study phs001343

• Novel optineurin frameshift insertion causing familial frontotemporal dementia and parkinsonism without amyotrophic lateral sclerosis

  Frontotemporal Dementia (FTD) is a common cause of Young Onset Dementia and has diverse clinical manifestations involving behaviour, executive function, language and motor function, including parkinsonism. Up to 50% of FTD patients report a positive family history, supporting a strong genetic basis, particularly in cases with both FTD and amyotrophic lateral sclerosis (FTD-ALS). Mutations in three genes are associated with the majority of familial FTD (fFTD) cases - microtubule associated protein tau gene (MAPT), progranulin gene (PGRN), and hexanucleotide repeat expansions in chromosome 9 open reading frame 72 (C9orf72), whilst mutations in other genes such as optineurin (OPTN) have rarely been reported. Mutations in OPTN have been reported mostly in familial and sporadic cases of ALS, or in rare cases of FTD-ALS, but not in association with pure or predominant FTD and/or parkinsonian phenotype. Here, we report for the first time, a family from the Philippines with 4 affected members harbouring the same OPTN frameshift insertion, presenting with FTD-related phenotypes, including one sibling with predominant parkinsonism resembling corticobasal syndrome. Notably, none of the affected members showed any evidence of motor neuron disease or ALS at the time of writing, both clinically and on electrophysiological testing, expanding the phenotypic spectrum of OPTN mutations. Close follow-up of mutation carriers for the development of new clinical features and wider investigation of additional family members with further genetic analyses will be conducted to investigate the possibility of other genetic modifiers in this family which could explain phenotypic heterogeneity.

  Study EGAS00001005220

• CINECA synthetic data.Please note: This study contains synthetic data (with cohort “participants” / ”subjects” marked with FAKE) has no identifiable data and cannot be used to make any inference about cohort data or results.

  Please note: This study contains synthetic data (with cohort “participants” / ”subjects” marked with FAKE) has no identifiable data and cannot be used to make any inference about cohort data or results. The purpose of this dataset is to aid development of technical implementations for cohort data discovery, harmonization, access, and federated analysis. In support of FAIRness in data sharing, this dataset is made freely available under the Creative Commons Licence (CC-BY). Please ensure this preamble is included with this dataset and that the CINECA project (funding: EC H2020 grant 825775) is acknowledged. For any questions please contact isuru@ebi.ac.uk or cthomas@ebi.ac.uk

  Study EGAS00001002472

• LUD2015-005 Trial Data Access Committee

  Dac EGAC00001002863